GeneHealth - Your precision medicine

Glaucomatocyclitic Crisis

Disease Details

Family Health Simplified

Buy Membership

Description: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, is a rare ocular condition characterized by recurrent episodes of elevated intraocular pressure accompanied by mild anterior uveitis and typically without significant pain or vision loss.
Type: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, does not have a specific type of genetic transmission. It is generally considered idiopathic, meaning its exact cause is unknown and it is not typically associated with a hereditary pattern.
Signs And Symptoms: Ocular hypertension (IOP 30
Prognosis: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, generally has a good prognosis. The condition is characterized by recurrent episodes of elevated intraocular pressure and mild inflammation in the eye. These episodes can usually be managed effectively with medications that lower intraocular pressure and anti-inflammatory agents. While the recurrent nature of the condition can be concerning, it often does not lead to significant long-term vision loss if appropriately treated and monitored. However, close follow-up with an ophthalmologist is essential to prevent potential complications.
Onset: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, typically has a sudden onset. This condition is characterized by recurrent episodes of elevated intraocular pressure accompanied by mild inflammation of the anterior chamber of the eye.
Prevalence: There is no comprehensive data on the exact prevalence of glaucomatocyclitic crisis. This condition, also known as Posner-Schlossman syndrome, is relatively rare. It typically affects adults between the ages of 20 and 50.
Epidemiology: It usually affects adults between the ages of twenty and fifty and is common in males than females. One study from Finland found that the incidence of disease is 0.4 and its prevalence is 1.9 out of 100,000.
Intractability: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, is generally not considered intractable. It often involves recurrent episodes of elevated intraocular pressure with mild anterior uveitis. These episodes can typically be managed effectively with medications such as intraocular pressure-lowering drugs and corticosteroids. However, long-term management and regular monitoring may be required to control and prevent recurrent episodes.
Disease Severity: Glaucomatocyclitic crisis, also known as Posner-Schlossman Syndrome, typically manifests as short-term episodes of elevated intraocular pressure accompanied by mild inflammation in the eye. The severity can vary; while the condition often results in temporary symptoms, it can cause significant discomfort during attacks and may lead to optic nerve damage if not properly managed. As there is a potential risk for vision impairment, timely medical intervention is crucial to manage intraocular pressure and mitigate long-term effects.
Healthcare Professionals: Disease Ontology ID - DOID:9378
Pathophysiology: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, involves recurrent episodes of markedly elevated intraocular pressure (IOP), typically without significant optic nerve damage or visual field loss. The pathophysiology is not completely understood but involves a form of inflammatory trabeculitis leading to impaired aqueous humor outflow. This inflammation is likely associated with an abnormal immune response, potentially triggered by viral infections such as cytomegalovirus (CMV) or herpes simplex virus (HSV). Elevated prostaglandins in the aqueous humor have also been implicated in the pathogenesis.
Carrier Status: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, does not have a carrier status as it is not a genetic disease. It is characterized by recurring episodes of elevated intraocular pressure and mild inflammation of the eye, particularly affecting the trabecular meshwork. If you have other specific queries related to this condition, please provide further details.
Mechanism: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, is characterized by recurrent episodes of elevated intraocular pressure (IOP) along with mild anterior uveitis.

**Mechanism:**
- **Intraocular Pressure:** Episodes of markedly elevated IOP, often exceeding 40 mm Hg, occur due to impaired outflow of aqueous humor.
- **Uveitis:** Mild inflammation of the anterior uvea (iris and ciliary body) is present during episodes.

**Molecular Mechanisms:**
- **Immune Response:** An autoimmune response or viral infection (e.g., cytomegalovirus or herpes simplex virus) has been implicated. This response might lead to inflammation that affects the trabecular meshwork, reducing aqueous humor outflow.
- **Prostaglandins and Cytokines:** Increased production of prostaglandins and cytokines during the inflammatory response can contribute to changes in aqueous humor dynamics and IOP elevation.

Understanding the exact molecular mechanisms is still an active area of research, but immune-mediated and viral etiologies are strongly suspected contributors.
Treatment: Main aim of treatment is to reduce IOP and decrease inflammation.
Compassionate Use Treatment: For glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, there are no specific compassionate use or experimental treatments widely recognized. However, treatment generally focuses on managing inflammation and elevated intraocular pressure. Some off-label or investigational treatments include:

1. **Anti-VEGF Therapy**: Reducing intraocular pressure, although traditionally used for macular degeneration.
2. **Immunomodulatory Drugs**: Medications like methotrexate for patients with severe or recurrent inflammation.
3. **Biologics**: Agents like adalimumab, used primarily in autoimmune uveitis, may be considered for severe cases.

These treatments should be considered under strict medical guidance and monitoring.
Lifestyle Recommendations: For Glaucomatocyclitic Crisis, also known as Posner-Schlossman syndrome, here are some lifestyle recommendations:

1. **Regular Eye Exams**: Maintain regular follow-up visits with an ophthalmologist to monitor intraocular pressure and overall eye health.

2. **Medication Adherence**: Strictly follow prescribed treatments, such as intraocular pressure-lowering medications.

3. **Healthy Diet**: Consume a balanced diet rich in fruits, vegetables, and omega-3 fatty acids which support overall eye health.

4. **Hydration**: Stay well-hydrated, but avoid excessive caffeine as it may increase eye pressure in some individuals.

5. **Exercise**: Engage in regular physical activity, which can help maintain overall health. However, avoid exercises that involve straining or inverted positions, which can increase eye pressure.

6. **Manage Stress**: Implement stress-reducing techniques such as yoga, meditation, or deep-breathing exercises, as stress can affect blood pressure and eye health.

7. **Protect Eyes**: Use protective eyewear to prevent trauma or injury to the eyes, which can exacerbate the condition.

8. **Avoid Smoking and Alcohol**: Refrain from smoking and limit alcohol consumption, as these can have adverse effects on eye health.

Individual recommendations may vary, so always discuss lifestyle changes with your healthcare provider.
Medication: For glaucomatocyclitic crisis, which is also known as Posner-Schlossman syndrome, treatment typically involves medications to lower intraocular pressure (IOP) and reduce inflammation. Commonly used medications include:

1. **Topical Glaucoma Medications**:
- Beta-blockers (e.g., timolol)
- Alpha agonists (e.g., brimonidine)
- Carbonic anhydrase inhibitors (e.g., dorzolamide)
- Prostaglandin analogs (e.g., latanoprost)

2. **Corticosteroids**:
- Topical corticosteroids (e.g., prednisolone acetate) to reduce inflammation

3. **Oral Medications** (if needed for significant IOP reduction):
- Acetazolamide, an oral carbonic anhydrase inhibitor

It is crucial to follow a healthcare professional’s advice for proper diagnosis and personalized treatment.
Repurposable Drugs: Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, is a type of secondary glaucoma characterized by recurrent episodes of elevated intraocular pressure with mild anterior uveitis. There are currently no widely recognized repurposable drugs specifically for glaucomatocyclitic crisis. Treatment typically involves the use of topical corticosteroids to reduce inflammation and medications to lower intraocular pressure, such as beta-blockers, prostaglandin analogs, or carbonic anhydrase inhibitors.

Research into repurposable drugs may be ongoing, so keeping up with recent studies and clinical trials could provide new insights in the future.
Metabolites: In glaucomatocyclitic crisis (Posner-Schlossman syndrome), specific research about unique metabolites is limited. However, the condition can be related to inflammatory processes and increased intraocular pressure, suggesting potential involvement of common inflammatory mediators and metabolic changes affecting aqueous humor dynamics. Further detailed metabolomic studies are required for precise identification.
Nutraceuticals: Nutraceuticals for glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, are not well-established. Management primarily relies on conventional medications such as corticosteroids to reduce inflammation and medications to lower intraocular pressure. Nutraceuticals like omega-3 fatty acids, antioxidants, or certain vitamins may support overall eye health but are not specifically indicated for this condition. Consultation with an eye care professional is essential for appropriate treatment.
Peptides: There is no direct and well-established connection between peptides and glaucomatocyclitic crisis in the current medical literature. Glaucomatocyclitic crisis, also known as Posner-Schlossman syndrome, is characterized by recurrent episodes of elevated intraocular pressure and mild anterior uveitis. While research on peptides in ophthalmology is ongoing, there's no specific peptide treatment widely recognized or approved for this condition. For precise and personalized treatment options, consulting a healthcare professional is essential.